Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups

(MedPage Today) -- Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial.
The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations...